[This review was originally posted at the Nieman Journalism Lab on Aug. 15, 2014.] This week’s essential reads: This week’s […]
[This review was originally posted at the Nieman Journalism Lab on Oct. 19, 2012.] Free speech and anonymity on Reddit: […]
[This review was originally posted at the Nieman Journalism Lab Cephalexin Dosage, on May 25, 2012.]
Facebook’s quick fall: A week ago, Facebook had just launched the largest, most buzzworthy initial public offering in years. And now, that IPO has already brought them a potentially massive lawsuit and a federal investigation. Aside from the whole “pocketing millions upon millions of dollars” thing, it’s been a brutal week for Facebook execs. Here’s what happened.
Facebook dominated the conversation online last week (GigaOM has a good roundup from last Friday’s IPO), and a lot of that wasn’t positive, kjøpe Cephalexin på nett, köpa Cephalexin online. As data from Pew’s Project for Excellence in Journalism showed, much of the chatter online, particularly on Twitter, was about Facebook as an overhyped (and overvalued) stock, Cephalexin Dosage. Those online observers may have been more right than they knew: As reports from Reuters, Business Insider (two posts), and The Wall Street Journaldetailed, Facebook was allegedly telling top investors they had overestimated their projected financial figures, all while publicly talking up their earning potential and even expanding their stock offering to the rest of us. The result, My Cephalexin experience, so far, has been a U.S. Securities and Exchange Commission investigation and a (potentially class-action) lawsuit from investors.
There were a number of good analyses of what went wrong — at The Guardian, Heidi Moore laid out the list of sins involved and concluded, “Facebook didn’t know how to work its own privacy settings for investors. It couldn’t figure out, essentially, who should know what.” Reuters’ Felix Salmon was more specific with his list of incompetents, Cephalexin for sale, declaring that the only winners in this game were the ones who didn’t play at all. The Big Picture’s Barry Ritholtz also ripped apart the debacle Cephalexin Dosage, .
The whole scandal still leaves open the question of what Facebook should, in fact, be valued at. At Technology Review, Michael Wolff was most provocative with his assessment, Cephalexin without a prescription, arguing that Facebook is just another business inextricably reliant on a fatally flawed online advertising model: “The crash will come. And Facebook—that putative transformer of worlds, which is, in reality, only an ad-driven site—will fall with everybody else,” he wrote. Harvard’s Doc Searls echoed Wolff’s thoughts about the brokenness of Facebook’s (and the web’s) ad model, and media consultant Terry Heaton countered that the broken industry isn’t the ad-supported web, Cephalexin reviews, but Madison Avenue’s insistence on the status quo on that web.
Others looked more closely at the future of Facebook’s services and of the social web more generally, Cephalexin Dosage. The Atlantic’s Alexis Madrigal wondered whether Facebook’s users would keep sharing and what would become of its native and mobile users, and ReadWriteWeb’s Dan Frommer examined the company’s four biggest risks (there’s mobile and advertising again!). There were other problems spotted: All Things D’s Peter Kafka looked at the continued decline of Facebook’s Social Reader apps, and The New York Times’ Nick Bilton contrasted Facebook and Twitter’s approaches to privacy. Tech blogger Dave Winer insisted that we can do better than Facebook, What is Cephalexin, while Slate’s Farhad Manjoo contended that Facebook has improved Silicon Valley.
The end of an era for New Orleans news: The American newspaper industry absorbed another big blow this week when the New Orleans Times-Picayune announced that it would drop back from daily publication to just three days a week, a change accompanied by the creation of a new corporate entity to run the paper and heavy layoffs — possibly a third of the newsroom. Cephalexin Dosage, The change will leave New Orleans as the largest city in the U.S. without a daily newspaper.
The news was broken by The New York Times’ David Carr, and according to the New Orleans alt-weekly Gambit, Times-Picayune employees learned of the paper’s fate through his report. (They later got this memo from the paper’s publisher.) All this came despite the fact that, Cephalexin schedule, as Jim Romenesko reported, the paper remains profitable. For some of the background on the paper — which is owned by Advance Publications, a division of the Newhouse publishing empire — see this post at the Columbia Journalism Review. (Advance also announced they’d be doing the same thing with three of its Alabama papers, led by the Birmingham News.)
Media analyst Ken Doctor has an extremely useful analysis of what exactly Advance/Newhouse is trying to accomplish with this move, and what perils it faces, Cephalexin Dosage. Doctor called the paper’s transition to digital a “forced march” because the paper simply isn’t ready for a digital transformation, particularly in terms of digital circulation. Purchase Cephalexin online, Others were similarly skeptical: The immediate comparison was to Advance’s 2009 transition of the daily Ann Arbor News to AnnArbor.com, and Forbes’ Micheline Maynard gave a bleak picture of what’s left of that news organization and the hole it’s left in the community.
Forbes’ John McQuaid, a former Times-Picayune reporter, described the way Advance’s web strategy has been “only lightly tethered to newsgathering,” and concluded that “with Advance, news has always been an adjunct to its vanilla branded sites, not something that is driving the internal business conversation, Cephalexin samples, and it shows.” And former Wall Street Journal writer (and Times-Picayune intern) Jason Fry said he doesn’t see any reason for optimism that Advance will get the web right in this case.
Free Press’ Josh Stearns noted that while the future-of-news world has been optimistically focused on experiments to sustain quality journalism in certain hubs like San Francisco, Chicago, and New York, they need to pay closer attention to mid-sized cities like New Orleans, where the infrastructure simply isn’t there to pick up the journalism being cut at major traditional news organizations.
What’s behind Buffett’s newspaper buy?: I briefly mentioned Warren Buffett’s purchase Cephalexin Dosage, late last week of 63 newspapers from Media General in last week’s review, but some smart commentary has come out about the deal since then (along with a few other pieces I missed at the time), so it’s worth touching on again. Cephalexin long term, Media analyst Ken Doctor did a sharp rundown of the deal, pointing out that the upside of Media General’s broadcast properties and the real estate involved with the newspapers Buffett’s buying should help buffer him from the inherent danger of buying a set of newspapers. Reuters’ Jack Shafer pointed out several of Buffett’s past bearish statements about newspapers, but said he’s most likely buying because he sees an undervalued asset, not for any sentimental reason.
The Columbia Journalism Review’s Justin Peters and The Washington Post’s Erik Wemple both explained why these papers might be surprisingly valuable for Buffett: While major metro dailies have taken a beating, smaller community newspapers in rural areas have weathered the digital storm fairly well so far, in part because of their monopoly on local news and the slower rates of broadband adoption there, online buy Cephalexin without a prescription.
Former journalism professor Philip Meyer made a similar point, arguing that Buffett is the type of buyer who’s happy with the new normal of lower profit margins for newspapers: “It looks like he is betting that the slide in newspaper earning power has leveled out. The Internet has done all the damage it can, and papers still make money.” PaidContent’s Jeff John Roberts looked at the economic sense Buffett’s paywall plan makes, while media consultant Dan Conover said he should be open to other non-paywall-based models, Cephalexin Dosage. Poynter’s Andrew Beaujon, meanwhile, said we may be ignoring another big reason for news org purchases like Buffett’s — they’re a platform for personal philosophies of how journalism should be done. Buffett did tell his new papers’ publishers that he would be hands-off with them, Cephalexin dosage, and that he expected to buy more small and mid-sized papers.
The bill, which was supposedly meant as a weapon against cyber-bullying and attacks against “local businesses and elected officials,” was predictably (and rightly) met with derision from scholars and those on the web. Columbia’s Tim Wu told The Guardian the bill was “an obvious first amendment violation, Cephalexin blogs,” and the bill was also ripped at sites like Techdirt and Animal. BetaBeat reported that some of the lawmakers involved with the bill were surprised by the blowback about it, while The Atlantic brought out a dissenting opinion, with a point/counterpoint on the value of anonymous online discourse.
— The Wall Street Journal reported on some of the ongoing struggles with AOL’s hyperlocal journalism project, Patch, Comprar en línea Cephalexin, comprar Cephalexin baratos, breaking the news that 20 Patch employees were being laid off and that one of AOL’s major investors is trying to get Patch killed, sold, or put into a joint venture. Jeff Bercovici of Forbes said it’s going to take a lot more cost-cutting or revenue-raising to get Patch to profitability by next year, and The Washington Post’s Erik Wemple said hyperlocal journalism’s business model doesn’t have room for executives in suits, Cephalexin Dosage.
— The New York Times’ public editor, Arthur Brisbane, will leave his position in September after two years, declining an optional third year. The Washington Post’s Erik Wemple, Cephalexin from canadian pharmacy, who broke the story, took the opportunity to criticize his most recent column, and Poynter’s Craig Silverman proposed five qualifications for the next public editor of the Times. Poynter also held a chat about the role of ombudsmen with Washington Post ombudsman Patrick Pexton and Reuters’ Jack Shafer.
— This week in Murdoch was a relatively quiet one. Cephalexin Dosage, News Corp. was reported to be considering spinning off its British newspapers — the Sun, the Times, and the Sunday Times — in order to preserve the rest of its media empire, something Murdoch denied but the Columbia Journalism Review’s Emily Bell saw as quite sensible. Here at the Lab, Ken Doctor examined what a trust for those papers might look like.
— A couple of interesting pieces of survey data discussed this week: The study that drew most of the headlines was one that looked at the political knowledge of audiences for various news outlets, finding NPR’s listeners to be the most informed and Fox News’ viewers to be the least informed. Another study found that about half of media professionals abandon websites when they hit a paywall.
— Finally, a couple of cool pieces on data journalism — Simon Rogers of The Guardian urged us to take on the punk “anyone can do it” mindset toward data journalism, and Alex Howard of O’Reilly Radar talked with former Guardian digital editor Emily Bell about her efforts to put data journalism into action with students at Columbia University.
Similar posts: Synthroid Dosage. Cipro For Sale. Cipro Dosage. Cheap Zoloft. Generic Bactrim. Real brand Cipro online.
Trackbacks from: Cephalexin Dosage. Cephalexin Dosage. Cephalexin Dosage. Cephalexin from canada. Cephalexin wiki. No prescription Cephalexin online.
[This review was originally posted at the Nieman Journalism Lab Buy Retin A No Prescription, on Aug. 12, 2011.]
Murdoch passes Wall Street's test: The fallout from News Corp.'s phone hacking scandal continued to spread this week, with the reported arrest of another former News of the World editor and the report that the ostensibly fired News Corp. British chief, Rebekah Brooks, Retin A alternatives, is still on the company payroll.
Three weeks after testifying before Parliament, Rupert Murdoch faced Wall Street analysts this week in a conference call, telling them that he's not going anywhere and that the scandal hasn't done any material damage to the company outside of News of the World. Purchase Retin A, All Things Digital's Peter Kafka said Wall Street really doesn't care about the hacking, and Murdoch didn't say much about the few questions he did get on it.
Murdoch also had to meet with News Corp.'s board, but as the New York Times' Jeremy Peters reported, the board's officially independent members include numerous people who have deep personal ties to Murdoch, Buy Retin A No Prescription. Perhaps more troubling was a different connection among one of the board members: According to Time's Massimo Calabresi, one of them is "best friends" with the district attorney leading the U.S. investigation into the company.
The Times' David Carr uncovered more hints at News Corp.'s enormous political influence here in the States, Retin A pics, detailing cases of swift approval of a merger by a Justice Department unit led by a future News Corp. executive, as well as a suspiciously dropped federal criminal case. "The company’s size and might give it a soft, less obvious power that it has been able to project to remarkable effect, Buy Retin A without prescription, " Carr concluded. Buy Retin A No Prescription, At Adweek, Murdoch biographer Michael Wolff went further, reporting that the Justice Department is considering investigating News Corp. on racketeering charges, though Forbes' Jeff Bercovici doubted that would happen. For a bit more info on the situation, here's a good Q&A with Nick Davies, the Guardian reporter who's been all over the story, order Retin A no prescription.
AOL's slap from investors: This week hasn't been a good one for AOL: After it reported a quarterly loss on Tuesday, its stock dropped by about a quarter by the end of the day. All Things Digital's Peter Kafka gave a quick explainer of why investors are so down on AOL: What little money they're making isn't coming from the all-important display advertising business. Mathew Ingram of GigaOM added more depth to that analysis, arguing that investors are doubting AOL's assurances that its two big gambles — Patch and the acquisition of the Huffington Post — will pay off, Buy Retin A No Prescription.
According to AOL CEO Tim Armstrong (paraphrased by Business Insider), Retin A price, coupon, the reason for those problems is that AOL's advertising side hasn't scaled well enough. Peter Kafka explained that AOL's advertising (especially display) is indeed up, though much of that can be attributed to the HuffPo and TechCrunch acquisitions. Forbes' Jeff Bercovici said AOL's public image problem has even damaged the previously successful HuffPo, quoting an analyst who called AOL a "dead brand." Wired's Tim Carmody decided to unite our two big stories this week and suggested that AOL would be a perfect fit for a purchase by News Corp.
Meanwhile's AOL's local-news initiative, Retin A samples, Patch, launched a Groupon-esque daily deal service, and Iowa grad student Robert Gutsche Jr.questioned Patch's standards for separating journalism and advertising — and got the runaround from Patch when he asked them about it. AOL's new daily tablet magazine, Editions, Buying Retin A online over the counter, also drew some criticism, with Fast Company's Austin Carr perturbed that it's not AOL-y enough.
A news org gets into tablets Buy Retin A No Prescription, : We've already seen numerous challengers to the iPad's early stranglehold on the tablet marketplace, but the Tribune Co. might be the first news company to try one out. CNN's Mark Milian reported that the newspaper chain is working on an Android-based tablet, which it's planning on offering it for free or very cheap to people who sign up for extended newspaper subscriptions. It's already missed a mid-August deadline for testing the tablet out, purchase Retin A online.
Media pundits didn't think much of the Tribune's idea. Wired's Tim Carmody urged the Tribune (and media companies in general) to quit developing tablets, arguing that it's way too hard to do if you're a major development company, let alone a news organization. "If major publishers are seriously prepared to blow up their primary revenue stream — print advertising — and slap together a giveaway tablet in order to save money on ink, God help them," he wrote, Buy Retin A No Prescription.
Others echoed Carmody's arguments: PaidContent's Tom Crazit called the project "a colossal waste of money for a company trying to emerge from bankruptcy." Chris Velazco of TechCrunch said the cheap-tablet model (also being talked about by Philadelphia Newspapers) isn't viable. Gizmodo's Brent Rose was less restrained: "WHY??" Morris Communications' Steve Yelvington was a little kinder to the Tribune, saying the numbers might add up, Kjøpe Retin A på nett, köpa Retin A online, but the devil's in the details.
The Times gets experimental: The New York Times has frequently made strong pushes into news innovation over the past several years, and this week it started another one, launching a new public test kitchen for projects in development. The Lab's Megan Garber explained what the site, beta620, Retin A for sale, is all about, but GigaOM's Mathew Ingram, while applauding the effort, expressed some doubt about whether the Times is really capable of developing a startup's mindset. Buy Retin A No Prescription, Tim Carmody of Wired, on the other hand, said the startup analogy isn't the right one for the Times. Retin A online cod, With these projects, he said, "The New York Times has become an openly experimental public institution. It’s less a cathedral consecrated to its own past than a free museum where patrons are invited to touch and transform everything they see." Poynter's Jeff Sonderman had some suggestions for next steps for the Times to take with beta620: experimenting with design, getting away from the long narrative article, and rethinking comments, Retin A trusted pharmacy reviews.
The real-name debate: One long-simmering debate I want to briefly catch you up on: Google+ has decided to take the Facebook route of disallowing pseudonyms, adjusting but reaffirming its policy in the face of online criticism late last month and again on Thursday. The outcry continued, voiced most prominently late last week by social media researcher danah boyd, Order Retin A from mexican pharmacy, who asserted that "'real names' policies aren’t empowering; they’re an authoritarian assertion of power over vulnerable people."
Liz Gannes of All Things Digital said she understands Google's motivations for enforcing real names and unifying everything under its umbrella within the same identity, but the idea of doing the latter is awkward at best and frightening at worst. The Atlantic's Alexis Madrigal, meanwhile, announced he's changed his mind against real-name policies, arguing that requiring real names online is a radical departure from the relationship between speech and identity in the offline world, Buy Retin A No Prescription.
Reading roundup: A few other things to keep an eye on this week:
— Amazon released a version of its Kindle app for browsers, called the Kindle Cloud Reader. GigaOM's Mathew Ingram said the browser-based e-book app (which bypasses Apple's restrictions) could be a roadmap for the future of the web, but Wired's Tim Carmody said it still doesn't get the web, Retin A without prescription.
— Google announced it's making its hand-chosen Editors' Picks a standing feature on Google News. The Lab's Megan Garber explained what Google's doing with it. Buy Retin A No Prescription, Meanwhile, James Gleick at The New York Review of Books offered a thoughtful piece on Google's domination of our online lives.
— Adweek explained an underrated obstacle to innovation and progress in news organizations' online efforts: the intractable CMS.
— Steve Buttry, now with the Journal Register Co., gave his lessons from TBD's demise on the Washington local news site's first birthday. It's short but solid. Enjoy.
Similar posts: Purchase Retin A. Order Cephalexin. Buy Zoloft No Prescription. Armour for sale. Where can i buy Cephalexin online. Synthroid without prescription.
Trackbacks from: Buy Retin A No Prescription. Buy Retin A No Prescription. Buy Retin A No Prescription. Retin A duration. Retin A images. Retin A australia, uk, us, usa.
[This review was originally posted at the Nieman Journalism Lab Cipro For Sale, on June 24, 2011.]
The New York Post's iPad block: News Corp. head Rupert Murdoch has developed a reputation for draconian policies toward paid content and the web, and he furthered that pattern this week when News Corp.'s New York Post blocked access to its website from the iPad's Safari browser in an effort to sell more of its iPad apps. A subscription to the app runs $6.99 per month; access to the website would be free.
The reaction on the web was overwhelmingly negative: Tech pioneer Dave Winer accused the Post of "breaking the web," paidContent's Staci Kramer called it "one of the most poorly conceived paywall efforts I’ve come across, buy Cipro from mexico," and business journalist Adam Tinworth called the move "dictatorial." As Kramer and Examiner.com's Michael Santo noted, the Post left plenty of workarounds for users who don't want to pay up, through alternative browsers like Skyfire. Kramer and Engadget's Dana Wollman also suspected that Murdoch is attempting to recreate the Post as an app-based tabloid like his other major effort, Cipro reviews, The Daily. (Both are skeptical about the prospects of that plan.)
News Corp, Cipro For Sale. does have some good news on the iPad front this week, though: The Post and The Daily are the two highest-grossing publishing apps on the iPad, ranking well ahead of the next-most-lucrative apps — two comic-book apps and Conde Nast's New Yorker and Wired.
Poynter's Regina McCombs talked to three other iPad app publishers — CNN, the Greensboro (N.C.) News & Record, Cipro trusted pharmacy reviews, and Better Homes & Gardens — about how they put their apps together. And the Columbia Journalism Review's Zachary Sniderman compared the iPad's adoption process to that of print periodicals before it: The iPad's sales, he said, "mirror a long trend of historical adoption rates and cultural attitudes: initial enthusiasm for a new platform, Online Cipro without a prescription, slow adoption, and then gradually increasing sales as the population gets habituated to using the new technology."
A fresh round of news innovation: This week was a big one in news innovation, as the Knight Foundation (one of the Lab's funders) announced the 16 winners of the last round of its five-year Knight News Challenge competition. The Lab's Joshua Benton gave a good annotated roundup of the winning entries, which will get a total of $4.7 million: There are a few names many people will recognize, including former New York Times/ProPublica project DocumentCloud, Cipro images, the AP's (and the Lab's) Jonathan Stray, and the crisis text-mapping service Ushahidi. Cipro For Sale, I would expect profiles of several of the winning projects over the next week or so, and the Lab's Justin Ellis provided the first with a look at the Chicago Tribune's PANDA, which aims to help newsrooms analyze data more easily. GigaOM's Mathew Ingram noticed the data journalism theme running through the winning entries, and elsewhere, Where can i buy cheapest Cipro online, the Daily Dot's Nicholas White opined on the importance of data in journalism.
Benton's post also included a glance at what's next for the News Challenge, as well as highlights of what has and hasn't gone well over the News Challenge's short history from a recently released internal review. Some of the main challenges: Underestimated difficulty of citizen journalism and news game projects, problems with accurate cost budgeting, and a slow timetable, Cipro forum. Poynter's Jeff Sonderman also looked back at some of the lessons learned from the News Challenge.
The Knight Foundation also announced a three-year, $3.76 million investment in MIT's Center for Future Civic Media, which named Berkman Center researcher Ethan Zuckerman its new director, Cipro For Sale. The Lab's Andrew Phelps talked to Zuckerman about where the center is headed, and Zuckerman looked at his goals in a post of his own. Mathew Ingramwondered whether the center can help with the ongoing reinvention of local journalism. Japan, craiglist, ebay, overseas, paypal, —
Two legal wins for aggregators: Rulings were handed down this week in two cases that probably only media-law nerds have following, but both have big implications for online news aggregation and link journalism. In the first case, a federal court ruled that a financial site can publish analysts' stock tips immediately, a blow to a legal principle called the "hot news doctrine" that protects certain facts ("hot news") from being republished for a short period of time. (Here's a great explainer Cipro For Sale, of the case from last year.)
This was one of those rulings where everyone declares victory: The court actually upheld the validity of the hot news doctrine in the Internet/aggregation era, but said it didn't apply in this case — the analysts are newsmakers and the website is the news breaker, the judge wrote. As Dealbook noted, Cipro pictures, the lawyer for Google and Twitter (who filed anti-hot news doctrine briefs) called it "a great decision for the free flow of information in the new media age," while the pro-hot news AP called it "a victory for the news media and the public." But as paidContent's Joe Mullin argued, it looks as though this decision will ultimate weaken the hot news doctrine.
In the other case, Where to buy Cipro, the copyright enforcement firm Righthaven had its lawsuit on behalf of the Las Vegas Review-Journal dismissed. Righthaven had sued a message-board user for reposting a 19-paragraph Review-Journal editorial, but the judge ruled that the posting was protected under fair use because the editorial only contained five paragraphs of purely original opinions and because it was posted for noncommercial reasons.
A renewed debate over anonymity: There have been a handful of streams of discussion regarding anonymity online over the past few weeks that converged a bit this week, and I thought it might be helpful to summarize a couple of them briefly for you. Two weeks ago, a supposed lesbian blogger in Syria was unmasked as a middle-aged American grad student, prompting thoughtful responses from people like the Berkman Center's Ethan Zuckerman and on the role of participatory media and the Guardian's Dan Gillmor and the Berkman Center's Jillian York on the continued need for anonymity, Cipro For Sale.
And last week, discount Cipro, a couple photographed kissing in the streets amid riots in Vancouver was identified online and making the mainstream-media rounds within days, prompting questions about the end of anonymity by writers like the New York Times' Brian Stelter and Salon's Drew Grant. Meanwhile, former NPR ombudsman Alicia Shepard decried anonymous online commenting, Cipro maximum dosage, calling it "faux democracy" and urging news organizations to require commenters to use their real names.
GigaOM's Mathew Ingram drew on several of those developments to echo Gillmor's and York's defenses of anonymity, arguing that it's been a key part of healthy democracy, allowing people to speak to the powerful without fear of reprisal. (The AP's Jonathan Stray called it "the digital analog of right to free assembly.") "We shouldn’t toss that kind of principle aside so lightly just because we want to cut down on irritating comments from readers, or stop the occasional blogger from pretending to be someone they are not, buy Cipro from canada," Ingram wrote.
Reading roundup Cipro For Sale, : Here's what else happened at the intersection of journalism and technology this week:
— Outgoing New York Times executive editor Bill Keller, who's done a fair amount of Twitter-tweaking over the past month or so, gave an interview to Reuters in which he said the idea that he's opposed to social media is a misconception. But sociologist Zeynep Tufekci took issue with his idea that social media use leads to less time with "real-life" friends, and when Keller asked for evidence, she let him have it. Cipro price, The Knight Digital Media Center's Amy Gahran also defended social media's usefulness to journalists with some new Pew data.
— This Week in AOL: Two more former employees gave their own horror stories about working there — one a writer, the other from sales. AOL CEO Tim Armstrong also said he's considering paid content as part of the company's continued revamp, the Columbia Journalism Review's Ryan Chittum pondered the AOL Way and the journalistic "hamster wheel," and Poynter's Steve Myers said comparisons between the Huffington Post and the New York Times are unfounded, Cipro dangers.
— Finally, the interesting pieces on the FCC's recent report on the future of local news continue to trickle out. Here's a pointed analysis by the folks at Free Press and a two-part Columbia Journalism Review interview with the report's lead writer, Steven Waldman.
Similar posts: Bactrim Cost. Tramadol For Sale. Order Retin A. Buy Lipitor without prescription. Bactrim interactions. Effects of Lipitor.
Trackbacks from: Cipro For Sale. Cipro For Sale. Cipro For Sale. Cipro blogs. Rx free Cipro. Online buying Cipro hcl.